Allele-Selective Inhibition of Huntingtin Expression by Switching to an miRNA-like RNAi Mechanism
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
SUMMARY Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington’s Disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity. An ideal silencing agent would block expression of mutant HTT while leaving expression of wild-type HTT intact. We observe that fully complementary duplex RNAs targeting the expanded CAG repeat within HTT mRNA block expression of both alleles. Switching the RNAi mechanism towards that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (< 10 nM) and highly selective (>30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient derived cells. Potent, allele selective inhibition of HTT by mismatched RNAs provides a new option for developing HD therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Argonaute2 is the catalytic engine of mammalian RNAi
Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J.-J., Hammond, S. M., Joshua-Tor, L., & Hannon, G. J. (2004) · Science · doi:10.1126/science.1102513 · Cited by 2,796
Self-citationTrinucleotide repeat length instability and age of onset in Huntington's disease
Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Persichetti, F., Frontali, M., Folstein, S., Ross, C., Franz, M., Abbott, M., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-387 · Cited by 1,089 · cited 2×
“Half of patients with HD have mutant alleles with <45 CAG repeats (Duyao et al., 1993; MacDonald et al., 1993).”
BackgroundHarper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682 · cited 1×
“This hypothesis has been tested in several animal models using both antisense oligonucleotides and duplex RNAs, and reducing levels of mutant HTT has been shown to alleviate symptoms and prolong survival (Harper et al., 2005; DiFiglia et al., 2007; Boudreau et al., 2009; Gagnon, 2010).”
Kremer, B., Goldberg, P., Andrew, S. E., Theilmann, J., Telenius, H., Zeisler, J., Squitieri, F., Lin, B., Bassett, A., Almqvist, E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405193302001 · Cited by 602
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506 · cited 1×
“Improved delivery technologies (Smith et al., 2006; De Souza et al., 2009) are making nucleic acids a promising approach for neurodegenerative diseases.”
BackgroundPfister, E. L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M., Landwehrmeyer, B., Vonsattel, J.-P., Zamore, P. D., & Aronin, N. (2009) · Current Biology · doi:10.1016/j.cub.2009.03.030 · Cited by 261 · cited 2×
“…HTT allele often contains single-nucleotide polymorphisms that distinguish it from the wild-type allele, allowing short-interfering RNAs (siRNAs) to selectively target the mutant gene (Miller et al., 2003; Schwarz et al., 2006; van Bilsen et al., 2008; Pfister et al., 2009; Zhang et al., 2009).”
Background
Cited by
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Self-citationTowards the elements of successful insect RNAi
Scott, J. G., Michel, K., Bartholomay, L. C., Siegfried, B. D., Hunter, W. B., Smagghe, G., Zhu, K. Y., & Douglas, A. E. (2013) · Journal of Insect Physiology · doi:10.1016/j.jinsphys.2013.08.014 · Cited by 486
Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bezard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 392
Carroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N., Hung, G., Bennett, C. F., Freier, S. M., & Hayden, M. R. (2011) · Molecular Therapy · doi:10.1038/mt.2011.201 · Cited by 293
Metadata
- Authors
- Hu, J., Liu, J., & Corey, D. R.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 17
- Issue
- 11
- Pages
- 1183-1188
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W1988261092
- Cited by
- 106
- References
- 7
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allele-Selective Inhibition of Huntingtin Expression by Switching to an miRNA-like RNAi Mechanism. https://app.cochat.ai/papers/10.1016/j.chembiol.2010.10.013
- The paper
- Hu, J., Liu, J., & Corey, D. R. (2010). Allele-Selective Inhibition of Huntingtin Expression by Switching to an miRNA-like RNAi Mechanism. Chemistry & Biology. https://doi.org/10.1016/j.chembiol.2010.10.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.